Comparative Safety of Dipeptidyl Peptidase-4 Inhibitors Versus Sulfonylureas and Other Glucose-lowering Therapies for Three Acute Outcomes
Author:
Funder
Gouvernement du Canada | Canadian Institutes of Health Research
Publisher
Springer Science and Business Media LLC
Subject
Multidisciplinary
Link
http://www.nature.com/articles/s41598-018-33483-y.pdf
Reference51 articles.
1. Hampp, C., Borders-Hemphill, V., Moeny, D. G. & Wysowski, D. K. Use of Antidiabetic Drugs in the U.S., 2003–2012. Diabetes Care 37, 1367–1374 (2014).
2. Lipska, K. J. et al. Trends in Drug Utilization, Glycemic Control, and Rates of Severe Hypoglycemia, 2006–2013. Diabetes Care 40, 468–475 (2017).
3. Clemens, K. K. et al. Trends in Antihyperglycemic Medication Prescriptions and Hypoglycemia in Older Adults: 2002–2013. PLOS ONE 10, e0137596 (2015).
4. Liu, J. et al. Incretin based treatments and mortality in patients with type 2 diabetes: systematic review and meta-analysis. BMJ 357, j2499 (2017).
5. Gamble, J.-M. et al. Incretin-based medications for type 2 diabetes: an overview of reviews. Diabetes Obes. Metab. 17, 649–658 (2015).
Cited by 17 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. A Critical Review on the Long-Term COVID-19 Impacts on Patients With Diabetes;The American Journal of Medicine;2024-03
2. DPP-4 Inhibitors as a savior for COVID-19 patients with diabetes;Future Virology;2023-04
3. IMPACT OF ANTIDIABETIC DRUGS ON RISK AND OUTCOME OF COVID-19 INFECTION: A REVIEW;Military Medical Science Letters;2022-06-03
4. Acute diabetic complications and implications of glycated hemoglobin levels (HbA1c) in the emergency department – Experience from a tertiary care centre of South India;Medical Journal of Dr. D.Y. Patil Vidyapeeth;2022
5. SARS-CoV-2 and diabetes: A potential therapeutic effect of dipeptidyl peptidase 4 inhibitors in diabetic patients diagnosed with COVID-19;Metabolism Open;2021-12
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3